Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

被引：0
|
作者：
Charalampos Charalampous
Utkarsh Goel
Prashant Kapoor
Moritz Binder
Francis K. Buadi
Joselle Cook
David Dingli
Angela Dispenzieri
Amie L. Fonder
Morie A. Gertz
Wilson Gonsalves
Suzanne R. Hayman
Miriam A. Hobbs
Yi L. Hwa
Taxiarchis Kourelis
Martha Q. Lacy
Nelson Leung
Yi Lin
Rahma Warsame
Robert A. Kyle
S. Vincent Rajkumar
Shaji K. Kumar
机构：
[1] Mayo Clinic,Division of Hematology, Department of Internal Medicine
[2] Mayo Clinic,Division of Nephrology and Hypertension, Department of Internal Medicine
来源：
Blood Cancer Journal | / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens
    Phou, Samantha
    Costello, Caitlin
    Kopko, Patricia M.
    Allen, Elizabeth S.
    [J]. TRANSFUSION, 2021, 61 (07) : 2054 - 2063
  • [22] DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (≥75 YEARS) PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES
    Mateos, M. -V.
    Spencer, A.
    Nooka, A.
    Pour, L.
    Weisel, K.
    Cavo, M.
    Laubach, J.
    Cook, G.
    Iida, S.
    Benboubker, L.
    Usmani, S. Z.
    Yoon, S. -S.
    Bahlis, N.
    Chiu, C.
    Schecter, J.
    Wu, K.
    Qin, X.
    Soong, D.
    Dimopoulos, M. A.
    [J]. HAEMATOLOGICA, 2017, 102 : 109 - 109
  • [23] Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naive Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics
    Snyder, Jordan
    Mansour, Razan
    Mammadzadeh, Aytaj
    Hashmi, Hamza
    Afrough, Aimaz
    Alkharabsheh, Omar
    Paul, Barry
    Atrash, Shebli
    Mushtaq, Muhammad Umair
    Skikne, Barry S.
    Ahmed, Nausheen
    Abdallah, Al-Ola
    [J]. BLOOD, 2023, 142
  • [24] First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma: Analysis of Different Clinical Scenarios
    Fonseca, Rafael
    Facon, Thierry
    Hashim, Mahmoud
    Nair, Sandhya
    He, Jianming
    Ammann, Eric M.
    Lam, Annette
    Wildgust, Mark
    Kumar, Shaji
    [J]. BLOOD, 2021, 138
  • [25] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Hannah A. Blair
    [J]. Drugs, 2017, 77 : 2013 - 2024
  • [26] Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
    Blair, Hannah A.
    [J]. DRUGS, 2017, 77 (18) : 2013 - 2024
  • [27] Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.
    Mateos, Maria-Victoria
    Spencer, Andrew
    Nooka, Ajay K.
    Pour, Ludek
    Weisel, Katja C.
    Cavo, Michele
    Laubach, Jacob
    Cook, Gordon
    Iida, Shinsuke
    Benboubker, Lotfi
    Usmani, Saad Zafar
    Yoon, Sung-Soo
    Bahlis, Nizar J.
    Chiu, Christopher
    Schecter, Jordan Mark
    Wu, Kaida
    Qin, Xiang
    Soong, David
    Dimopoulos, Meletios A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Listeria Susceptibility in Patients With Multiple Myeloma Receiving Daratumumab-Based Therapy
    Khan, Sahar
    Vaisman, Alon
    Hota, Susy S.
    Bennett, Sabrina
    Trudel, Suzanne
    Reece, Donna
    Tiedemann, Rodger E.
    [J]. JAMA ONCOLOGY, 2020, 6 (02) : 293 - 294
  • [29] Alloimmunization Rates and Transfusion Management of Multiple Myeloma Patients Receiving Daratumumab-Based Regimens
    Phou, Samantha
    Costello, Caitlin
    Kopko, Patricia
    Allen, Elizabeth S.
    [J]. TRANSFUSION, 2020, 60 : 223A - 224A
  • [30] Favorable outcomes of 3-weekly daratumumab-based regimens in relapsed/refractory multiple myeloma: impact of MRD, rapid doubling time, LDH, triplets and quadruplets
    Ngai, Cheong
    Tang, Hoi Ki Karen
    Fung, Chi Yeung
    Hwang, Yu Yan
    Wong, Kai Chung Vincent
    Chim, Chor Sang
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S184 - S184
12345